# Resolving the Mobility-Equity-Emissions Trilemma: A Causal Machine Learning Framework for Dynamic Tolling Policy

Article · Christian Mulomba Mukendi

- Archive id: arxiv:2610.33994
- Published: 2026-10-25
- Venue: Journal of Intelligence and Information Systems 32 (2026) 383-412
- DOI: https://doi.org/10.13088/jiis.2026.32.3.383
- arXiv: https://arxiv.org/abs/2610.33994
- Citations: 0
- Source URL: https://arxiv.org/abs/2610.33994
- PDF: https://arxiv.org/pdf/2610.33994
- Provenance: arxiv

## Abstract

We propose a causal machine learning framework to integrate dynamic tolling for mobility, equity, and climate objectives, resolving a long-standing policy trilemma. Using Double Machine Learning, we estimate zone-type-specific treatment effects, showing that commercial zones yield nearly twice the delay reduction of residential zones. Our adaptive quota mechanism expands residential coverage 34-fold while preserving 93% of total delay savings and sustaining high return on investment. The framework delivers climate co-benefits, reducing emissions by 743.5 metric tons of CO2 (valued at 141 USD) via congestion-sensitive pricing under moderate traffic conditions with sensitivity bounds from 557.6 to 929.3 tons. Crucially, we uncover a policy-invariant toll range where performance remains robust across demand scenarios, simplifying implementation. This study reveals critical, previously unidentified insights, such as a policy-invariant toll range, that can significantly simplify real-world implementation. Validated on synthetic data mirroring real-world networks, our methodological advances lay the foundation for future public deployment.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Scaling Laws & Compute-Optimal Training](https://space-kitty.com/topics/scaling-laws)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.